Patient P-02268

Synthetic patientMETA-24 · Day 175 · 65–74 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Improving

Discontinuation risk

74%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 21 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 71 GI-04 recommended — GI Support Protocol GI-04
Day 72 Patient accepted — Started GI-04 in the companion
Day 80 GI symptom burden −21% vs expected — GI Support Protocol GI-04
Day 84 ME-01 recommended — Monitoring Escalation ME-01
Day 85 Patient accepted — Started ME-01 in the companion
Day 86 Tolerance state changed — Unstable → Improving
Day 88 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 21.

Primary contributors, last 14 days

Toxicity+12
Treatment adherence-9
Nutritional resilience+5
Inflammatory activity+2

What helped?

GI Support Protocol GI-04Day 71
Result: symptom burden −21%
Monitoring Escalation ME-01Day 84
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

66%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

38 min

worsening · -1.6 vs previous 14 d

Sleep duration

Wearable

7.3 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

3.4/10

worsening · -0.2 vs previous 14 d

Steps

Wearable

3,206

worsening · -151 vs previous 14 d

GI burden

Companion

53.5/100

stable · -0.7 vs previous 14 d

Adherence

Companion

41.1 %

worsening · -3.7 vs previous 14 d

Sleep quality

Wearable

37.7/100

stable · -0.0 vs previous 14 d

Glucose, CGM daily mean

CGM

147 mg/dL

stable · +3.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 29 from the failing basin, 59 from restoration.

Would help

NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 78%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 78%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 78%
More protein
GI -4.3 next day on high-intake days · n 21

Would not help

Keep ultra-processed low
GI +5.6 next day on high-intake days · n 20
Keep histamine low
GI +5.2 next day on high-intake days · n 22
Keep fat low
GI +4 next day on high-intake days · n 23

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Ultra-processed food
+5.6detractor · 95%
Histamine load
+5.2detractor · 95%
Protein
-4.3supporter · 95%
Dietary fat load
+4detractor · 95%
Simple carbohydrates
+2.6detractor · 64%
Caffeine
+0.3no signal · 15%
Insoluble fibre
+0.2no signal · 15%
Alcohol
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 52
- WearableHRV 23 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 42/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 54 and rising
Drug metabolism and exposure ↑20
- BloodToxicity index 56
Autonomic recovery ↓20
- Wearable3,206 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 1.9 · butyrate capacity 42/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 26 ms
Sleep: 7.0 h
Steps: 3,272
Resting HR: 70 bpm

Daily log: GI score 54, nutritional resilience 43, adherence 41.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02048	19%	S02	—	—	77
P-02115	21%	S14	GI-04	improved	75
P-02575	22%	S14	ME-01	improved	73
P-02550	20%	S01	—	—	70
P-02192	19%	S05	—	—	69
P-02659	23%	S09	—	—	69
P-02293	19%	S15	HY-01	no change	68
P-02591	34%	S13	—	—	68
P-02090	19%	S04	—	—	68
P-02265	30%	S07	GI-04	no change	67
P-02530	32%	S07	—	—	67
P-02194	19%	S03	—	—	67